Collectively, we show that GIPR agonism and antagonism decrease body weight via different mechanisms, with GIPR antagonism, unlike agonism, depending on functional GLP-1R signalling
This is a signal-discovery instrument: proportions are among side-effect-disclosing posters rather than population rates, and symptom posts are structurally under-represented against progress posts, so it supports vocabulary and theme prominence, not magnitude
With the rising global prevalence of metabolic diseases like obesity and type 2 diabetes, the demand for glucagon-like peptide-1 (GLP-1) receptor agonist drugs continues to grow
10.1016/S0014-5793(99)01402-7 FEBS Lett
However, if you were a true non-responder to Saxenda (no appetite change, no weight loss despite proper adherence), you might still respond to semaglutide, but response isnt guaranteed